Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. (29th January 2018) - Knox, J J; Barrios, C H; Kim, T M; Cosgriff, T; Srimuninnimit, V; Pittman, K; Sabbatini, R; Rha, S Y; Flaig, T W; Page, R D; Beck, J T; Cheung, F; et al.